{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.9","upperLimit":"31.5","value":"24.2"},{"groupId":"OG001","lowerLimit":"6.6","upperLimit":"16.8","value":"11.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"164"}],"units":"Participants"}],"description":"To assess improvement of symptoms based on the total symptom score (TSS); a responder was defined as having achieved a clinically relevant reduction from Baseline of the TSS. The scale consists of 30 items in 7 subscales (skin, eye, mouth, lung, nutrition, energy, and psychological). Participants reported their level of symptom \"bother\" over the previous month on a 5-point likert scale: not at all, slightly, moderately, quite a bit, or extremely. Subscale scores and the summary score range from 0 to 100, with a higher score indicating worse symptoms.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ruxolitinib was administered orally twice per day at a dose of 10 milligrams (mg).","id":"OG000","title":"Ruxolitinib"},{"description":"Participants received best available therapies (BATs), including, but not limited to, extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), infliximab, rituximab, pentostatin, imatinib, and ibrutinib based on the investigator's decision.","id":"OG001","title":"Best Available Therapy"}],"paramType":"NUMBER","populationDescription":"FAS. Data reported are from the start of the study to Cycle 7 Day 1 (data cutoff of 08 May 2020).","reportingStatus":"POSTED","timeFrame":"Baseline; Cycle 7 Day 1 (each cycle was comprised of 4 weeks)","title":"Rate of Participants With Clinically Relevant Improvement of the Modified Lee cGvHD Symptom Scale Score","type":"SECONDARY","unitOfMeasure":"percentage of participants"}